(Q33344377)

English

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

Anna Dmoszyńska

7

object named as

Anna Dmoszyńska

1 reference

Europe PubMed Central

26 July 2017

Jadwiga Dwilewicz-Trojaczek

8

object named as

Jadwiga Dwilewicz-Trojaczek

1 reference

Europe PubMed Central

26 July 2017

Andrzej Hellmann

5

object named as

Andrzej Hellmann

1 reference

Europe PubMed Central

26 July 2017

6

object named as

Lech Konopka

1 reference

Europe PubMed Central

26 July 2017

1

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

26 July 2017

Joanna Góra-Tybor

4

object named as

Joanna Góra-Tybor

1 reference

Europe PubMed Central

26 July 2017

Dariusz Wolowiec

9

object named as

Dariusz Wołowiec

1 reference

Europe PubMed Central

26 July 2017

Marek Kasznicki

3

object named as

Marek Kasznicki

1 reference

Europe PubMed Central

26 July 2017

Jerzy Z. Blonski

2

object named as

Jerzy Z Boński

1 reference

Europe PubMed Central

26 July 2017

author name string

Polish Leukemia Study Group

10

1 reference

Europe PubMed Central

26 July 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

26 July 2017

European Journal of Haematology

1 reference

Europe PubMed Central

26 July 2017

69

1 reference

Europe PubMed Central

26 July 2017

27-36

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

21 January 2018

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02711.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0609.2002.02711.X

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33344377&oldid=1756476820"